Abstract
Pre-Exposure Prophylaxis (PrEP) is one of the preventive measures for HIV infection in population with substantial risk such as Men who have Sex with Men (MSM), transgender women, people who inject drugs (PWID) and heterosexual HIV-1 sero-discordant couples. In Thailand, PrEP service has been supported by governmental bodies and private sectors, from both national and international levels. This service is run as a pilot programme and is available only in certain areas. It is also not included in any health coverage schemes. For more effective prevention against HIV as well as for keeping AIDs problems under control by 2030, the Department of Disease Control, Ministry of Public Health, had proposed an inclusion of such service into the Universal Health Coverage Benefit Package (UCBP). The service was selected for evaluation with health technology assessment, in which economic evaluation and budget impact analysis were conducted. Health Intervention Technology Assessment Programme (HITAP) was assigned from the subcommittee of Health Benefit Package, National Health Security Office, to conduct an economic evaluation of the PrEP service, which covers both Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC), as well as related laboratory tests. The evaluation was performed in order to aid the decision making process of whether to include the aforementioned service into the UCBP.
